Proviral Turnover During Untreated HIV Infection Is Dynamic and Variable Between Hosts, Impacting Reservoir Composition on ART.
HIV
persistence
proviral half-life
reservoir
within-host phylogenetic analysis
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
06
2021
accepted:
30
07
2021
entrez:
7
9
2021
pubmed:
8
9
2021
medline:
8
9
2021
Statut:
epublish
Résumé
Human immunodeficiency virus (HIV) can persist as an integrated provirus, in a transcriptionally repressed state, within infected cells. This small yet enduring pool of cellular reservoirs that harbor replication-competent HIV is the main barrier to cure. Entry of viral sequences into cellular reservoirs begins shortly after infection, and cells containing integrated proviral DNA are extremely stable once suppressive antiretroviral therapy (ART) is initiated. During untreated HIV infection however, reservoir turnover is likely to be more dynamic. Understanding these dynamics is important because the longevity of the persisting proviral pool during untreated infection dictates reservoir composition at ART initiation. If the persisting proviral pool turns over slowly pre-ART, then HIV sequences seeded into it during early infection would have a high likelihood of persisting for long periods. However, if pre-ART turnover was rapid, the persisting proviral pool would rapidly shift toward recently circulating HIV sequences. One-way to estimate this turnover rate is from the age distributions of proviruses sampled shortly after therapy initiation: this is because, at the time of sampling, the majority of proviral turnover would have already occurred prior to ART. Recently, methods to estimate a provirus' age from its sequence have made this possible. Using data from 12 individuals with HIV subtype C for whom proviral ages had been determined phylogenetically, we estimated that the average proviral half-life during untreated infection was 0.78 (range 0.45-2.38) years, which is >15 times faster than that of proviral DNA during suppressive ART. We further show that proviral turnover during untreated infection correlates with both viral setpoint and rate of CD4+ T-cell decline during this period. Overall, our results support dynamic proviral turnover pre-ART in most individuals, which helps explain why many individuals' reservoirs are skewed toward younger HIV sequences. Broadly, our findings are consistent with the notion that active viral replication creates an environment less favorable to proviral persistence, while viral suppression creates conditions more favorable to persistence, where ART stabilizes the proviral pool by dramatically slowing its rate of decay. Strategies to inhibit this stabilizing effect and/or to enhance reservoir turnover during ART could represent additional strategies to reduce the HIV reservoir.
Identifiants
pubmed: 34489909
doi: 10.3389/fmicb.2021.719153
pmc: PMC8417368
doi:
Types de publication
Journal Article
Langues
eng
Pagination
719153Subventions
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI051231
Pays : United States
Informations de copyright
Copyright © 2021 Brooks, Omondi, Liang, Sudderuddin, Jones, Joy, Brumme, Hunter and Brumme.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past collaboration with the authors ZB and CB.
Références
PLoS Pathog. 2016 Aug 05;12(8):e1005689
pubmed: 27494508
AIDS. 2003 Sep 5;17(13):1871-9
pubmed: 12960819
J Virol. 2017 Jun 9;91(13):
pubmed: 28404854
Nat Med. 2003 Jun;9(6):727-8
pubmed: 12754504
Clin Infect Dis. 2014 Nov 1;59(9):1322-31
pubmed: 25038116
JCI Insight. 2020 Feb 27;5(4):
pubmed: 32045386
PLoS One. 2008 Apr 16;3(4):e1954
pubmed: 18414658
Front Immunol. 2019 Aug 22;10:1966
pubmed: 31507594
AIDS. 2018 Sep 24;32(15):2113-2118
pubmed: 30005008
Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9523-8
pubmed: 22645358
Curr Opin HIV AIDS. 2015 Jan;10(1):18-28
pubmed: 25415421
Sci Transl Med. 2019 Oct 9;11(513):
pubmed: 31597754
Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8783-8
pubmed: 27432972
N Engl J Med. 2016 Jun 2;374(22):2120-30
pubmed: 27192360
PLoS Pathog. 2020 Feb 5;16(2):e1008286
pubmed: 32023326
Nat Med. 2016 Sep;22(9):1043-9
pubmed: 27500724
J Infect Dis. 2013 Oct 15;208(8):1202-11
pubmed: 23852127
PLoS Pathog. 2012;8(4):e1002615
pubmed: 22496643
J Virol. 1997 Mar;71(3):2233-40
pubmed: 9032358
PLoS One. 2012;7(3):e33948
pubmed: 22479485
Nat Commun. 2019 Feb 13;10(1):728
pubmed: 30760706
Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8958-E8967
pubmed: 30185556
Trends Immunol. 2020 Jun;41(6):466-480
pubmed: 32414695
Lancet HIV. 2018 Jan;5(1):e35-e44
pubmed: 28978417
Cell. 2013 Oct 24;155(3):540-51
pubmed: 24243014
EBioMedicine. 2016 Sep;11:68-72
pubmed: 27460436
J Infect Dis. 2021 Feb 3;223(2):225-233
pubmed: 32823274
PLoS Pathog. 2020 Jun 3;16(6):e1008378
pubmed: 32492044
J Infect Dis. 2015 Nov 1;212(9):1361-5
pubmed: 25877550
J Antimicrob Chemother. 2013 May;68(5):1169-78
pubmed: 23335199
Elife. 2016 Nov 15;5:
pubmed: 27855060